Northwest Biotherapeutics is a biotech company focused on developing immunotherapy products to treat cancers more effectively than current treatments, eliminating toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. NBWO’s lead program is a 312-patient phase 3 trial in newly diagnosed glioblastoma multiforme (GBM), the most aggressive and lethal form of brain cancer. For more information visit the company’s Web site at www.nwbio.com
Let us hear your thoughts below: